Tag: Non-Small Cell Lung Cancer
AstraZeneca Halts Phase III eVOLVE-Lung02 Trial of Volrustomig in Advanced Lung Cancer
AstraZeneca has announced it is stopping its Phase III eVOLVE-Lung02 study, which was testing volrustomig combined with chemotherapy as a first-line treatment for metastatic non-small cell...
AstraZeneca Licenses Novel Lung Cancer Drug Zegfrovy in $1.5B Global Deal
AstraZeneca announced a exclusive global license agreement with Dizal Pharmaceutical to develop and commercialize Zegfrovy (sunvozertinib), a highly differentiated, oral irreversible EGFR inhibitor designed for targeted lung cancer...
